|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma analyses revealed a significant increase in OPN and MMP-9 levels and activity in patients with prostate cancer in association with clinical variables (prostate-specific antigen > 4 ng/mL and Gleason score > 7).
|
19010864 |
2008 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vivo studies using athymic nude mice injected with CWR22Rv1 (22Rv1) PCa epithelial cells and CAF cells ± ERα also confirmed that mice coimplanted with PCa cells and CAF ERα+ cells had less tumor foci in the pelvic lymph nodes, less metastases, and tumors showed less angiogenesis, MMP3, and MMP9 (an MMP3 downstream target) positive staining.
|
24374826 |
2014 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MMP-9 activity was higher and statistically significant in PCa than in BPH (p≤0.01).
|
27931798 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There were no differences in activities of MMP-2, proMMP-9, and MMP-9/NGAL (neutrophil gelatinase associated lipocalin) complex (gelatin substrate) in men with detected prostate cancer, although the latter two were somewhat diminished.
|
29175302 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in-silico results indicated that the expression of MMP-9 in cancer tissue was higher than that in normal tissue in prostate cancer (Transcripts Per Kilobase Million (TPM) = 7.14 vs. 1.36, P < 0.001), bladder cancer (TPM = 14.2 vs. 2.47, P < 0.001), kidney renal clear cell carcinoma (TPM = 7.43 vs. 1.61, P < 0.001), kidney renal papillary cell carcinoma (TPM = 5.52 vs. 1.74, P = 0.002).
|
30249503 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP.
|
21391788 |
2011 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Co-cultures of PC and stromal cells showed enhanced levels of pro-MMP-9 and reduced levels of TIMP-1 and TIMP-2.
|
11477554 |
2001 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
We extended these studies and more recently observed increased expression of genes related to angiogenesis such as vascular endothelial growth factor (VEGF) and those related to metastasis such as matrix metalloproteinases (MMP)-2 and MMP-9 in prostate cancer of TRAMP mice.
|
12840218 |
2003 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
|
14605668 |
2003 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that CNF1 derived from UPEC plays an important role in PCa progression through activating a Cdc42-PAK1 signal axis and up-regulating the expression of MMP-9.
|
28707808 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate the contribution of MMP-26 to cancer cell invasion via the activation of MMP-9, highly invasive and metastatic human prostate carcinoma cells, androgen-repressed prostate cancer (ARCaP) cells were selected as a working model.
|
12586837 |
2003 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
LIV-1 overexpressed ARCaP(E) cells had elevated levels of HB-EGF and matrix metalloproteinase (MMP) 2 and MMP 9 proteolytic enzyme activities, without affecting intracellular zinc concentration.
|
22110740 |
2011 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This is the first report suggesting that VES inhibits human prostate cancer cell invasiveness and the reduction of secreted MMP-9 activity could be one of the contributory factors, which points to the potential use of VES in the prevention and therapy of prostate cancer invasion.
|
15048090 |
2004 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, this study evidences MMP-9 as an essential factor for the activation of the chain of the different MMPs and consequently in the genesis and development of bone metastasis of PCa due to its influence on bone osteoblastic and osteoclastic activity.
|
29650324 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data showed that knockdown of SPAG9 in prostate cancer cell lines inhibited cell motility and invasion due to the inactivation of metalloproteinase-2 (MMP‑2)/MMP-9 by upregulation of tissue inhibitor of metalloproteinase-1 (TIMP-1)/TIMP-2.
|
25310386 |
2014 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Silencing of LASS2/TMSG1 gene in PC-3M-2B4 cells increased V-ATPase activity, extracellular hydrogen ion concentration and in turn the activation of secreted MMP-2 and MMP-9, which coincided with enhancing cell proliferation, cell survival, and cell invasion in vitro, as well as acceleration of prostate cancer (PCA) growth and lymph node metastases in vivo.
|
24453046 |
2014 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Consequently, LOX-1 activation by oxLDL promotes actin cytoskeleton restructuration and MMP-2 and MMP-9 activity inducing prostate cancer cell invasion and migration.
|
29107109 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that inhibition of NF-kappaB DNA binding activity by B-DIM contributes to the regulated bioavailability of VEGF by MMP-9 and uPA and, in turn, inhibits invasion and angiogenesis, which could be mechanistically linked with the antitumor activity of B-DIM as observed previously by our laboratory in a prostate cancer animal model.
|
17409440 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The PCa stem cell increase then led to the upregulation of matrix metalloproteinase 9, ZEB-1, CD133 and CXCR4 molecules, and enhanced the metastatic ability of PCa cells.
|
23792449 |
2014 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Based on these exciting results, we propose that loss of PDEF along with increased MMP9 expression should serve as novel markers for early detection of aggressive prostate cancer.
|
20550708 |
2010 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Previously, we showed that binding of the chemokine CXCL12 to its receptor CXCR4 mediated signaling events resulting in matrix metalloproteinase-9 expression in prostate cancer bone metastasis.
|
18337451 |
2008 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
This method was successfully verified by detecting MMP-9 in clinical serum samples of prostate cancer.
|
31660560 |
2019 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further mechanistic investigations showed that Nur77 inhibited transcription of TGF-β target genes (Snail and MMP9), and thereby inhibits TGF-β-mediated prostate cancer cell invasion following androgen antagonism.
|
29594945 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer.
|
31381135 |
2020 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
FLI1 and MMP9 position differently in prostate cancer than in normal tissue and prostate hyperplasia, whereas MMP2 is repositioned in both prostate cancer and hyperplasia.
|
26564800 |
2016 |